| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5634627 | World Neurosurgery | 2017 | 36 Pages |
Abstract
Our results from an unselected cohort of recurrent HGGs show that the currently available treatment options have no negative impact on HRQoL. Thus, treatment decisions can be made individually, without fear of jeopardizing HRQoL for better survival. Only, the third recurrent surgery remains a very individual decision even in younger patients with high Karnofsky Performance Score.
Keywords
HGGGlobal health statusCCNUGHSTMZBEVEORTC QLQ-C30HRQOLKPSQOLPCBQuality of lifeoverall survivalbevacizumabTemozolomideRecurrent surgeryWorld Health OrganizationChemotherapyLomustineKarnofsky performance scorePCV یا Pneumococcal conjugate vaccinevincristineProcarbazineWHOHealth-related quality of lifeGlioblastomaHigh-grade glioma
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Linda Stöckelmaier, Mirjam Renovanz, Jochem König, Katrin Nickel, Anne-Katrin Hickmann, Regine Mayer-Steinacker, Minou Nadji-Ohl, Oliver Ganslandt, Lars Bullinger, Christian Rainer Wirtz, Jan Coburger,